TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 170 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 6.30 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $162,753 | -42.4% | 18,205 | -1.0% | 0.00% | – |
Q2 2023 | $282,347 | -21.2% | 18,382 | +15.4% | 0.00% | – |
Q1 2023 | $358,266 | +1.2% | 15,930 | -5.4% | 0.00% | – |
Q4 2022 | $353,998 | -56.1% | 16,833 | -48.6% | 0.00% | -100.0% |
Q3 2022 | $807,000 | -46.3% | 32,747 | -47.2% | 0.00% | 0.0% |
Q2 2022 | $1,504,000 | +565.5% | 62,045 | +753.8% | 0.00% | – |
Q4 2021 | $226,000 | -18.4% | 7,267 | -36.5% | 0.00% | – |
Q3 2021 | $277,000 | +42.8% | 11,442 | -14.0% | 0.00% | – |
Q2 2021 | $194,000 | -66.4% | 13,298 | -42.5% | 0.00% | – |
Q1 2021 | $577,000 | -7.7% | 23,113 | +0.9% | 0.00% | – |
Q4 2020 | $625,000 | – | 22,903 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |